SPONSORED EPISODE: Europe’s ambition to stop cancer

详细摘要
Europe is a leader in cancer research. But turning that science into treatments that reach patients is another matter. Every minute, five people in Europe are diagnosed with…
Europe is a leader in cancer research. But turning that science into treatments that reach patients is another matter. Every minute, five people in Europe are diagnosed with cancer, and the disease costs the European economy more than €200 billion a year.
Five years after its launch, Europe’s Beating Cancer Plan has been scrutinized by the European Court of Auditors and the European Parliament. Both back its ambitions but find delivery falling short, with national cancer plans often lacking the resources to succeed and access to care varying widely among member countries. Meanwhile, Europe’s share of global commercial clinical trials has almost halved in a decade.
With the EU’s proposed Biotech Act under negotiation and talks on the bloc’s next long-term budget under way, Europe has a chance to close the gap between innovation and access.
In the second of two special podcast episodes produced by POLITICO Studio, experts in cancer policy explore what Europe must do to ensure every patient benefits from innovations in cancer care, from speeding up clinical trials to giving patients a real voice in policymaking.
Hear from Elisabetta Zanon, chief executive of the European Cancer Organisation, which brings together cancer professionals and patients from across Europe; and Jennifer Young, VP and head of International Commercial Policy and Communications for Pfizer.
文章开头,摘自Politico Europe。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.politico.eu)




